Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2024, Volume and Issue: unknown, P. 167623 - 167623
Published: Dec. 1, 2024
Language: Английский
Journal of Endocrinological Investigation, Journal Year: 2024, Volume and Issue: 47(10), P. 2421 - 2436
Published: March 26, 2024
Language: Английский
Citations
15
Diabetes/Metabolism Research and Reviews, Journal Year: 2024, Volume and Issue: 40(3)
Published: March 1, 2024
Abstract Objective To identify the causal role of sodium‐glucose cotransporter 2 (SGLT2) inhibition on three urological cancers. Methods Six single nucleotide polymorphisms associated with expression level SLC5A2, a proxy for SGLT2 inhibition, from recent publication were extracted. Three common cancers, including bladder cancer, prostate cancer and kidney analysed. The main cohort was derived UK Biobank (1279 cases 372,016 controls). Prostate Cancer Association Group to Investigate Associated Alterations in Genome (PRACTICAL) consortium (79,148 61,106 phenotype 463,010 individuals (1114 461,896 Primary sensitivity analysis performed validate results. In vitro also incorporated Mendelian randomisation Results primary analysis, reduced risk (OR: 0.98, 95% CI: 0.97–0.99) per unit lowering HbA1c level. A protective association observed odds ratio = 0.31 (95% CI 0.21–0.47). However, we did not discover relationship between 1.00, 0.99–1.00). Sensitivity validation support increasing risk. Conclusions We find any evidence that could increase Even some tended show effects
Language: Английский
Citations
10
Cellular & Molecular Biology Letters, Journal Year: 2024, Volume and Issue: 29(1)
Published: May 29, 2024
Abstract Background Sodium-glucose transporter 2 (SGLT2) inhibitors (iSGLT2) are approved medications for type diabetes. Recent studies indicate that iSGLT2 inhibit the growth of some cancer cells. However, mechanism(s) remains to be fully elucidated. Methods The SGLT2 levels were determined in normal colon CCD 841 CoN and, HCT 116, HT-29, SW480 and LoVo colorectal (CRC) cell lines by quantitative real-time PCR western blot. effect canagliflozin on proliferation was examined using CCK-8, as its role CRC cells metabolism tumorigenesis has been evaluated XF HS Seahorse Bioanalyzer flow cytometric analyses. Transient gene silencing experiments analysis protein–protein interaction network conducted evaluate molecular targets Results Data showed treatment with (50 µM) 72 h induced cycle arrest ( p < 0.001), impaired glucose energetic promoted apoptotic death ER stress flowing into autophagy 0.001) 116 HT-29 These cellular events accompanied sirtuin 3 (SIRT3) upregulation 0.01), also supported SIRT3 transient resulting attenuation effects metabolic/energetic alterations induction programmed death. identification validation dipeptidyl peptidase 4 (DPP4) potential common target assessed. Conclusions results deepened knowledge contribution limiting unveiling SGLT2/SIRT3 axis cytotoxic mechanisms. Graphical
Language: Английский
Citations
9
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: Feb. 7, 2025
This paper explored the novel approach of targeting cyclic guanosine monophosphate (GMP)-adenosine (AMP) synthase-stimulator interferon genes (cGAS-STING) pathway for treatment osteosarcoma (OS). Osteosarcoma is a common malignancy in adolescents. Most patients die from lung metastasis. It reviewed epidemiology and pathological characteristics OS, highlighting its highly malignant nature tendency pulmonary metastasis, underscoring importance identifying new therapeutic targets. The cGAS-STING was closely associated with biological behaviors OS cells, suggesting that this could be promising strategy. Currently, research on role has been limited, underlying mechanisms remain unclear. Therefore, further investigation into exploration strategies based are great significance developing more effective treatments OS. offered fresh perspective providing hope options by pathway.
Language: Английский
Citations
1
Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15
Published: Feb. 11, 2025
Tumor is a major challenge to global health and has received extensive attention worldwide due its high degree of malignancy poor prognosis. Although the clinical application targeted therapy immunotherapy improved status quo tumor treatment, development new therapeutic tools for tumors still necessary. Sodium-glucose transporter protein 2 (SGLT2) inhibitors are type glycemic control drugs, which widely used in practice because their effects on weight reduction protection cardiac renal functions. SGLT2 been found be overexpressed many involved tumorigenesis, progression metastasis, suggesting that SGLT2i wide range applications therapy. The aim this article provide comprehensive understanding research progress different by integrating latest studies encourage further exploration therapies trials. This could pave way more effective management strategies outcomes patients.
Language: Английский
Citations
1
Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15
Published: Aug. 6, 2024
Background The relationship between sodium-glucose cotransporter 2 (SGLT2) inhibitors and prostate cancer is still unknown. Although these can influence tumor glycolysis, the underlying mechanism requires further exploration. Methods A two-sample two-step MR was used to determine 1) causal effects of SGLT2 inhibition on cancer; 2) 1,400 circulating metabolites or metabolite ratios 3) mediation metabolites. Genetic proxies for were identified as variants in SLC5A2 gene glycated hemoglobin level (HbA1c). Additionally, positive control analysis type diabetes mellitus (T2DM) conducted test selection genetic proxies. Phenome Wide Association Study (PheWAS) MR-PheWAS explore potential treatable diseases adverse outcomes inhibitors. Results Genetically predicted (per 1 SD decrement HbA1c) associated with reduced risk T2DM [odds ratio (OR) = 0.66 (95% CI 0.53, 0.82), P 1.57 × 10 −4 ]; [0.34 (0.23, 0.49), 2.21 −8 ] prostate-specific antigen [0.26 (0.08, 0.81), 2.07 −2 ]. effect mediated by uridine level, a proportion 9.34% total effect. In MR-PheWAS, 65 traits found be SLGT2 ( < 1.78 −5 ), among them, 13 related diabetes. Conclusion Our study suggested that could lower through mediation. More mechanistic clinical research necessary how mediates link cancer.
Language: Английский
Citations
4
Molecular and Cellular Endocrinology, Journal Year: 2024, Volume and Issue: 588, P. 112225 - 112225
Published: April 1, 2024
Language: Английский
Citations
3
Diagnostic Pathology, Journal Year: 2025, Volume and Issue: 20(1)
Published: Jan. 8, 2025
Hepatoblastoma (HB) is the most common malignant solid tumor of liver in children and a fatal disease with poor prognosis. Therefore, indicators that can be used for early prediction HB prognosis are necessary. Sodium glucose cotransporter 2 (SGLT2) transporter protein present proximal renal tubules. Studies have shown SGLT2 associated occurrence tumors upregulated various tumors. Peroxiredoxin 4 (PRDX4) an antioxidant enzyme secretory function located cytoplasmic endoplasmic reticulum. Recent reports suggested it closely related to development cancers. To some degree, this highly suggestive interplay between PRDX4. In study, clinical data post-surgical paraffin-embedded specimens from 75 patients were collected, hematoxylin eosin immunohistochemical staining PRDX4 analyze their expression correlation clinicopathological features We found low high predicted significantly shorter survival worse condition patients. Furthermore, when was combined expression, event-free overall reduced. Univariate multivariate Cox proportional hazards analyses showed independent prognostic factors after surgical resection. The combination independently predict
Language: Английский
Citations
0
Anti-Cancer Drugs, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 9, 2025
Eugenol, a phenolic natural product with diverse pharmacological activities, remains unexplored in liver cancer. Using network pharmacology, we investigated eugenol’s therapeutic mechanisms We obtained molecular structure from PubChem and screened its targets using similarity ensemble approach Swiss Target Predictiondatabases. Overlapping genes cancer-related GeneCards were identified. Protein–protein interaction networks, Gene Ontology annotations, Kyoto Encyclopedia of Genes Genomes pathway analyses conducted. A target-pathway revealed 122 genes. Molecular docking confirmed high affinity for mitochondrial nicotinamide adenine dinucleotide, reduced form (NADH) dehydrogenase 1 (MT-ND1), AKT1, NDUFB7, NADH (complex I) subunit S3 (NDUFS3). Expression levels these normal cancer tissues examined GEPIA2 HPA databases. The CCK-8 assay colony formation demonstrated that eugenol significantly inhibited the proliferation hepatocellular carcinoma cells. Western blot analysis upregulated MT-ND1 while downregulating expression such as NDUFS3. Furthermore, it was found could influence AKT1 target through AKT/p70 S6K pathway. This study provides new insights into potential offers novel perspectives network-based research.
Language: Английский
Citations
0
Expert Review of Clinical Pharmacology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 31, 2025
To evaluate the association between sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and risk of neoplasm in patients with Type 2 diabetes (T2D). Literature retrieval was conducted using databases from inception to June 2024. Randomized controlled trials (RCTs) comparing SGLT-2i placebo or other treatments T2D, reports events were included. Results computed as ratio (RR) 95% confidence intervals (CI). A total 53 RCTs 126,232 participants No significant differences found for overall (RR = 1.08, CI: 0.99 1.19, I2 23%) treatment compared non-users. However, decreased pulmonary 0.83, 0.69 0.99, 0.0%) observed users non-users, while increased prostate 1.21, 1.00 1.47, 0.0%). Compared use not associated neoplasm. neoplasms less frequent users, an www.crd.york.ac.uk/prospero identifier is CRD42021273681.
Language: Английский
Citations
0